Tukysa, a tyrosine kinase inhibitor by Pfizer, delays disease progression in HER2-positive metastatic breast cancer. In a late-stage trial with 654 patients, it improved progression-free survival by 8 ...

Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...

Time to treatment initiation: An assessment of trends in delays in patients with lung cancer across Missouri. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...

By a News Reporter-Staff News Editor at Disease Prevention Daily-- A new study on Drugs and Therapies- Kinase Inhibitors is now available. Financial supporters for this research include Taiju Life ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...